Dechra Pharmaceuticals PLC Appointment of Non-Executive Director (7795O)
November 09 2016 - 9:54AM
UK Regulatory
TIDMDPH
RNS Number : 7795O
Dechra Pharmaceuticals PLC
09 November 2016
9 November 2016
Dechra(R) Pharmaceuticals PLC
(Dechra, Company or the Group)
Board Appointment
Appointment of Non-Executive Director
Dechra is pleased to announce that Lawson Macartney has been
appointed to the Board as Non-Executive Director with effect from 1
December 2016.
Dr Macartney, a qualified veterinarian, is Chairman of Viking
Therapeutics Inc., a developer of novel therapeutics for patients
suffering from metabolic and endocrine disorders, and an adviser to
several biopharmaceutical companies and life science consultancies.
Prior to this, Dr Macartney was President and CEO of Ambrx Inc.,
Senior Vice President and Head of Emerging Business at Shire AG,
and held various senior, global commercial, sales, marketing and
strategy roles at GlaxoSmithKline plc.
Ian Page, Chief Executive Officer, Dechra Pharmaceuticals
said:
"We are delighted to welcome Lawson to the Board and we look
forward to working with him. Lawson's 30 years of experience gained
in the global pharmaceutical industry will bring further knowledge
and expertise of product development to the Board."
There are no other disclosures to be made in respect of Lawson
Macartney, pursuant to Listing Rule 9.6.13R.
Enquiries to:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer
Office: +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director
Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and relates products business. Our expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
Market Abuse Regulation (MAR)
The information contained within this announcement may contain
inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014. Upon the publication of this announcement via
the Regulatory Information Service, this inside information is now
considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFSDFLUFMSEIF
(END) Dow Jones Newswires
November 09, 2016 09:54 ET (14:54 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024